Appendix 4C for the Quarter Ended 31 March 2026

Melbourne, Australia, 30th April 2026: Rhythm Biosciences Ltd ('**RHY**', the '**Company**' or the '**Group**') (**ASX: RHY**), a transformative, predictive cancer diagnostics technology company, today releases its business update and Appendix 4C for the quarterly period ended 31 March 2026 (**Q3 FY26**).

Overview

Rhythm delivered a defining quarter in Q3 FY26, marking its transition from development-stage to a commercial diagnostics company. The Company generated its first ColoSTAT® clinical revenue, activated national testing infrastructure, secured manufacturing scale, and commenced formal evaluation with NHS England, establishing the key foundations required for sustained commercial growth. Furthermore, the Company announced the conclusion of an exercise and underwriting of RHYO options.

Key Highlights

- ✓ **First ColoSTAT® clinical sale achieved**, marking initial revenue and validating real-world clinical adoption and commercial deployment.
- ✓ **NHS England laboratory evaluation commenced**, opening a potential independent pathway to UK and broader European markets.
- ✓ **Manufacturing scale secured via Quansys agreement**, establishing the supply chain and supporting future growth in test volumes.
- ✓ **National collection network activated through 4Cyte**, enabling broad patient access and reducing barriers to clinician adoption.
- ✓ **Regulatory and clinical foundations strengthened**, with NATA accreditation confirmed and leading clinician engagement expanding.
- ✓ **geneType™ commercial footprint expanded**, with new partnerships in Southeast Asia and Australia and launch of enhanced colorectal cancer risk test.
- ✓ **Strengthening of financial position through options exercise and underwriting,** over the quarter and through to 14th April 2026. The strong and encouraging support from options holders provides additional working capital to support the Company's commercial activities and drive sales of ColoSTAT® and geneType™ in both domestic and international markets

Rhythm Biosciences Managing Director and CEO, Dr David Atkins commented:

"Q3 FY26 is the quarter where commercialisation became real. The first ColoSTAT® clinical test sale is not just a financial milestone, it is proof that clinicians trust our technology and that patients are benefiting from it. The NATA audit completion, the NHS England evaluation, the Quansys supply agreement, the 4Cyte network activation - each of these removes a barrier between our technology and the patients who need it. These are not incremental steps; they are the infrastructure of a functioning commercial diagnostics business. Simultaneously, geneType™ is broadening its reach. The AGRF partnership

open significant new distribution channels, and the launch of our enhanced CRC risk test strengthens our clinical offering. Both platforms are now generating commercial momentum, and both are positioned for continued growth.

Finally, the Board is grateful for the encouraging support of our shareholders and option holders who have put the Company into a strong financial position. Their support ensures we remain focused on execution - scaling test volumes, deepening clinical engagement, and building the strategic partnerships that will define Rhythm's future. The opportunity is significant, the team is committed, and the momentum is with us."

Review of Q3 FY26 Stated Milestones

At the end of Q2 FY26, the Company committed to delivering the following milestones during Q3 FY26. We are pleased to report that all stated milestones were achieved:

- **NATA audit completion** — Completed 23 January 2026, further strengthening the accreditation framework supporting ColoSTAT® as an in-house IVD.
- **Continued geneType™ menu expansion** — The enhanced Colorectal Cancer Risk Assessment test was commercially launched in January 2026 as planned.
- **Further ColoSTAT® commercialisation and strategic partnerships** — First clinical test sale recorded; Access Program physician enrolment continued; 4Cyte collection network activated; Quansys supply agreement executed.
- **Additional domestic and international geneType™ partnerships** — Digistain, Southeast Asia and AGRF (Australia) partnerships announced.
- **Progression of ColoSTAT® supply arrangements** — Quansys Biosciences manufacturing agreement finalised, securing scalable production capability.
- **Commencement of NHS England ColoSTAT® analytical evaluation** — Evaluation formally commenced during Q3 FY26.

Company Product Portfolio

Rhythm's product portfolio comprises two complementary platforms that together address the continuum from cancer risk identification through to disease detection:

Disease Detection

ColoSTAT® is a minimally invasive, blood-based test for the detection of colorectal cancer (CRC). It measures five specific protein biomarkers and is intended for symptomatic individuals. With 91% sensitivity across all cancer stages (I–IV), it provides clinicians with a powerful tool to triage patients efficiently, directing those most likely to have cancer to prompt colonoscopy while sparing lower-risk individuals unnecessary procedures.

Cancer Risk Assessment

geneType™ is a sophisticated genetic risk assessment platform that combines polygenic risk scores with clinical, family history, and lifestyle data to generate personalised cancer risk assessments. It covers multiple conditions including breast cancer, colorectal cancer, ovarian cancer, prostate cancer, melanoma, and cardiovascular disease. Together with ColoSTAT®, geneType™ creates a powerful 'identify risk, detect disease' continuum.

ColoSTAT® Business Update: Commercialisation Takes Hold

NATA Audit Successfully Completed — 23 January 2026
The NATA (National Association of Testing Authorities) audit was successfully completed on 23 January 2026. This audit validated Rhythm's continued compliance with ISO 15189:2022—the international standard for medical testing laboratories—and is essential to the Company's ability to operate ColoSTAT® as an in-house IVD (In Vitro Diagnostic) test.

First ColoSTAT® Clinical Test Sale
Rhythm recorded its first commercial clinical ColoSTAT® test sale during Q3 FY26. This is the milestone the Company has been working toward since its founding in 2017—proof that a paying clinician has ordered the test for a real patient.

While initial test volumes are modest, the significance cannot be overstated: the product is validated, the laboratory is operational, the accreditation is in place, and clinicians are choosing to use ColoSTAT®. The commercial engine has turned over. The focus now is on growing the volume of tests as physician awareness and ColoSTAT® Access Program participation increases.

4Cyte Pathology Collection Network Activated
Activation of 4Cyte's national collection centre network is a major enabler of commercial scale. Previously, patient blood samples had to be collected through a limited number of pathology access points. With 4Cyte's extensive national footprint now accessible, patients across Australia can have samples collected conveniently at a location near them, and those samples are then sent to Rhythm's accredited laboratory for ColoSTAT® analysis.

ColoSTAT® Access Program — Physician Enrolment
The Access Program is the structured clinical pathway through which Australian clinicians can refer symptomatic patients for ColoSTAT® testing in conjunction with the collection of real-world evidence by the Company. Professor Finlay Macrae, one of Australia's foremost authorities in colorectal cancer genetics and hereditary bowel cancer syndromes, was enrolled as a member of the ColoSTAT® Access Program.

Quansys Biosciences Manufacturing Agreement
Rhythm executed a commercial supply agreement with Quansys Biosciences—a specialist immunoassay manufacturer—to support ColoSTAT® production at scale. The agreement secures access to the multiplexed immunoassay reagents at the heart of the ColoSTAT® test.

NHS England ColoSTAT® Analytical Evaluation by NHS Laboratory — Commenced
Our partner NHS laboratory commenced its analytical evaluation of ColoSTAT® during Q3 FY26. This represents an important step in the evaluation process, with NHS scientists independently assessing the analytical performance characteristics of the test. The NHS serves 60 million people and is one of the world's most rigorous healthcare systems. An independent, positive evaluation would provide world-class validation of ColoSTAT® and establish a potential commercial pathway into the United Kingdom.

geneType™ Business Update: Distribution and Revenue Growth

Q3 FY26 saw the platform's distribution footprint grow materially through two new partnership agreements.

geneType™ Southeast Asia — Digistain Partnership and First Commercial Sale
On 4 March 2026, Rhythm executed a Supply and Distribution Agreement with Digistain Limited, a UK-incorporated cancer diagnostics company with established commercial networks across Southeast Asia, to distribute the geneType™ test portfolio in the region. Within weeks of the Agreement's commencement, Rhythm announced the first commercial geneType™ test sale in Southeast Asia — completed in Manila, Philippines on 26 March 2026.

AGRF Reference Laboratory Partnership — Australia
A partnership was announced with the Australian Genome Research Facility (AGRF), one of Australia's leading genomics laboratories and a trusted reference facility for genomic testing across the country. The AGRF partnership strengthens geneType™'s domestic distribution and provides access to AGRF's existing clinical and research customer base. As Australian healthcare providers increasingly integrate genomic risk information into patient care, partnerships with established and trusted genomics providers are an efficient pathway to growing test volumes.

Enhanced geneType™ CRC Risk Assessment Test — Commercial Launch
The enhanced Colorectal Cancer Risk Assessment test was commercially launched in January 2026, on schedule following its ahead-of-plan development completion in Q2 FY26. The upgraded test incorporates additional clinical and lifestyle risk factors alongside the established 140-SNP polygenic risk score, delivering improved predictive accuracy across all genders and a wider age range.

This enhancement is particularly significant for women, who have historically been underserved by CRC risk models, and for younger adults presenting with early-onset colorectal cancer risk. By identifying individuals at elevated genetic risk, geneType™ creates a natural referral pathway for ColoSTAT® testing and colonoscopy—integrating the two platforms in a clinically meaningful way.

Corporate Update

RHYO Option Underwriting Completed
The underwriting by CPS Capital Group Pty Ltd ("CPS", the "Underwriter") of RHYO options expiring on 31 March 2026 has been completed.

Cash and Cash Equivalents as of 31 March 2026
Cash and cash equivalents on 31 March 2026 are set out in the accompanying Appendix 4C cash flow statement. Payments to related parties of the entity and their associates during the quarter are disclosed in accordance with ASX Listing Rule 5.3.5 and comprised director fees, salary, and superannuation only.

The Company continues to actively manage its cost base while investing in the commercial activities required to grow ColoSTAT® test volumes and geneType™ partnership revenues. Shareholders are referred to the formal Appendix 4C cash flow statement for detailed financial information.

Milestones We Expect to Deliver Before the End of Q4 FY26

Building on the momentum established in Q3, Q4 FY26 will be focused on growing test volumes and consolidating Rhythm's position as a commercial diagnostics business:

- Increase ColoSTAT® test volumes through the 4Cyte network and ColoSTAT® Access Program.
- Progress the NHS England laboratory ColoSTAT® analytical evaluation toward completion.
- Expansion of geneType™ domestic and international commercial partnerships.
- Advance strategic pathways for ColoSTAT® commercial expansion.

Looking Ahead: Building Commercial Momentum

Q3 FY26 delivered on every commitment made to shareholders and established the commercial foundations Rhythm needs to grow. The ColoSTAT® Access Program is live and generating revenue, the 4Cyte collection network is operational, the Quansys supply chain is secured, and NHS England has begun its evaluation. geneType™ has new distribution partners in Southeast Asia and Australia and a stronger product in the market.

The task in Q4 FY26 is clear: grow test volumes, deepen clinical engagement, advance the NHS England evaluation, and expand our partnership network. The infrastructure is in place. The regulatory foundations are solid. The clinical evidence is compelling.

Rhythm is no longer a development-stage company. It is a commercial diagnostics business with two revenue-generating platforms, growing clinical adoption, and a meaningful international pipeline. For shareholders who have supported this journey, the Company is grateful—and the best is ahead.

Related Party Payments

In line with its obligations under ASX Listing Rule 5.3.5, Rhythm Biosciences Limited notes that the only payments to related parties of the Company, as disclosed in the Appendix 4C for the period ended 31 March 2026, pertain to payments to directors for fees, salary, and superannuation.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.
For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to collaborating with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalised health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
RHYTHM BIOSCIENCES LIMITED	
ABN	**Quarter ended ("current quarter")**
59 619 459 335	31 MARCH 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	14	57
1.2	Payments for		
	(a) research and development	(633)	(2,367)
	(b) product manufacturing and operating costs	(221)	(796)
	(c) advertising and marketing		
	(d) leased assets		
	(e) staff costs (not included above)	(217)	(754)
	(f) administration and corporate costs	(301)	(1,258)
1.3	Dividends received (see note 3)		
1.4	Interest received	5	35
1.5	Interest and other costs of finance paid	(5)	(74)
1.6	Income taxes paid		
1.7	Government grants and tax incentives		1,576
1.8	Other		
1.9	**Net cash from / (used in) operating activities**	**(1,358)**	**(3,581)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		(1)
	(d) investments		
	(e) intellectual property		

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
	(f) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	3	3
	(d) investments		
	(e) intellectual property		
	(f) other		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	**Net cash from / (used in) investing activities**	**3**	**2**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		3,749
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	1,120	1,120
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(12)	(192)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings	(91)	(1,190)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	**Net cash from / (used in) financing activities**	**1,017**	**3,487**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,643	1,397
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,358)	(3,581)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	3	2

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,017	3,487
4.5	Effect of movement in exchange rates on cash held		
4.6	**Cash and cash equivalents at end of period**	**1,305 ***	**1,305 ***

* There is also $85k in term deposits able to be called upon if required.

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,305	1,643
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other – short term deposit		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,305 ***	**1,643 ***

* There is also $85k in term deposits able to be called upon if required.

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	141
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Payments in 6.1 relate to Director fees and salaries.

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	148	148
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**	148	148

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Clearmatch insurance funding loan. Unsecured. Interest rate: 9.06% p.a. Matures on 25/10/2026 with fixed monthly repayments.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,358)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,305
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,305
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.96

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Yes. The Company does expect to continue to have a similar level of net operating cash flows.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes. On 14 April 2026, the Company announced the successful exercise and underwriting of RHYO options. The Board is continuing to assess alternative capital sources, and the Directors believe that the Company can raise sufficient capital in the form of equity financing and or non-dilutive inflows. In addition, the Company has and will continue to employ cash management strategies.

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer:	On the basis of the responses above, the Company expects to be able to continue its operations and meet its business objectives as required under the Corporations Act.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: .....30 APRIL 2026.....

Authorised by: .....BY THE BOARD.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.